Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
40.20
+0.72 (1.82%)
Jul 16, 2024, 11:42 AM EDT - Market open

Mirum Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Cash & Equivalents
302.84286.33128131.34142.0911.97
Short-Term Investments
00123.72125.289.73104.69
Cash & Cash Equivalents
302.84286.33251.72256.54231.82116.66
Cash Growth
30.49%13.75%-1.88%10.66%98.71%-
Receivables
5567.9723.993.2700
Inventory
21.6122.315.571.5100
Other Current Assets
10.0210.94-91.05-94.734.532.7
Total Current Assets
389.47387.54190.23166.59236.35119.36
Property, Plant & Equipment
1.181.992.352.553.243.73
Long-Term Investments
0004.98023.29
Goodwill and Intangibles
257.44252.9358.9518.7400
Other Long-Term Assets
3.874.17101.38101.791.270.32
Total Long-Term Assets
262.5259.08162.68128.064.5127.35
Total Assets
651.96646.62352.91294.65240.86146.71
Accounts Payable
15.987.428.699.173.153.35
Current Debt
0.361.10.930.710.640.4
Other Current Liabilities
89.5778.5455.1132.7214.689.33
Total Current Liabilities
105.9187.0664.7342.618.4613.08
Long-Term Debt
307.16307.04141.61131.8350.283.25
Other Long-Term Liabilities
4.293.854.530.020.030.04
Total Long-Term Liabilities
311.45310.89146.14131.8450.313.29
Total Liabilities
417.36397.95210.87174.4468.7716.36
Total Debt
307.52308.14142.54132.5450.913.65
Debt Growth
114.03%116.18%7.55%160.32%1295.67%-
Retained Earnings
-581.52-556.24-392.82-257.16-173.17-69.9
Comprehensive Income
-0.011.64-0.22-0.040.080.13
Shareholders' Equity
234.6248.67142.04120.21172.1130.35
Net Cash / Debt
-4.68-21.82109.18124180.91113.01
Net Cash / Debt Growth
---11.95%-31.45%60.08%-
Net Cash Per Share
-0.10-0.533.214.097.169.84
Working Capital
283.56300.48125.5124217.89106.29
Book Value Per Share
5.006.084.203.966.8211.35
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).